Abstract
Barbiturate-induced anesthesia is a complex mechanism that probably involves several ligand-gated ion channel superfamilies. One of these superfamilies includes the archetypical nicotinic acetylcholine receptor (nAChR), in which barbiturates act as noncompetitive antagonists. In this regard, we used the Torpedo californica nAChR and a series of barbiturate analogs to characterize the barbiturate binding site(s) on this superfamily member. [14C]Amobarbital binds to one high-affinity (Kd = 3.7 μM) and several (∼11) low-affinity (Kd = 930 μM) sites on the resting and desensitized nAChRs, respectively. Characteristics of the barbiturate binding site on the resting nAChR include: (1) a tight structure-activity relationship. For example, the barbiturate isobarbital [5-ethyl-5′-(2-methylbutyl) barbituric acid] is >10-fold less potent than its formula isomer amobarbital [5-ethyl-5′-(3-methylbutyl) barbituric acid] in inhibiting [14C]amobarbital binding. (2) A binding locus within the pore of the nAChR ion channel. Each of the barbiturate analogs inhibited the binding of [3H]tetracaine or photoincorporation of 3-trifluoromethyl-3-(m-[125I]iodophenyl) diazirine in a mutually exclusive manner. (3) Stereoselective binding. The R(+)-enantiomers of isobarbital and pentobarbital are ∼2-fold more potent in inhibiting 3-trifluoromethyl-3-(m-[125I]iodophenyl) diazirine photoincorporation than the S(−)-enantiomers. Finally, molecular modeling suggests that within the channel, the pyrimidine ring of the barbiturate is located just above the highly conserved leucine ring (M2–9; e.g., δLeu-265), whereas the 5′ side chain projects downward, and depending upon its conformation, introduces steric hindrance to binding because of the restriction in the lumen of the channel introduced by the leucine side chains.
Footnotes
-
This research was supported in part by National Institutes of Health Grant R29-NS35786 (M.P.B.).
- Abbreviations:
- LGIC
- ligand-gated ion channel
- nAChR
- nicotinic acetylcholine receptor
- 5-HT3R
- type 3 5-hydroxytryptamine receptor
- GABAAR
- type A γ-aminobutyric acid receptor
- NCA
- noncompetitive antagonist
- [125I]TID
- 3-trifluoromethyl-3-(m-[125I]iodophenyl) diazirine
- [3H]TCP
- [piperidyl-3,4-3H (N)]-(N-(1-(2-thienyl)cyclohexyl)-3,4-piperidine
- PCP
- phencyclidine
- CCh
- carbamylcholine
- dansyltrimethylamine
- [1-(dimethylamino)-napthalene-5-sulfonamido]ethyltrimethylammonium perchlorate
- HPLC
- high-performance liquid chromatography
- amobarbital
- 5-ethyl-5′-(3-methylbutyl) barbituric acid
- amylbarbital
- 5-ethyl-5′-amyl barbituric acid
- isobarbital
- 5-ethyl-5′-(2-methylbutyl) barbituric acid
- pentobarbital
- 5-ethyl-5′-(1-methylbutyl) barbituric acid
- VDB
- vesicle dialysis buffer
- Received March 21, 2001.
- Accepted June 8, 2001.
- The American Society for Pharmacology and Experimental Therapeutics
MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|